KR20110086006A - 세포 증식을 위한 조사된 멤브레인 - Google Patents
세포 증식을 위한 조사된 멤브레인 Download PDFInfo
- Publication number
- KR20110086006A KR20110086006A KR1020117009458A KR20117009458A KR20110086006A KR 20110086006 A KR20110086006 A KR 20110086006A KR 1020117009458 A KR1020117009458 A KR 1020117009458A KR 20117009458 A KR20117009458 A KR 20117009458A KR 20110086006 A KR20110086006 A KR 20110086006A
- Authority
- KR
- South Korea
- Prior art keywords
- membrane
- cells
- membranes
- kgy
- cell
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 387
- 230000004663 cell proliferation Effects 0.000 title abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000001301 oxygen Substances 0.000 claims abstract description 29
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000001464 adherent effect Effects 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 238000010894 electron beam technology Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 188
- 239000012510 hollow fiber Substances 0.000 claims description 74
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 72
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 63
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 63
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 63
- 238000004113 cell culture Methods 0.000 claims description 31
- 239000004814 polyurethane Substances 0.000 claims description 26
- 229920002492 poly(sulfone) Polymers 0.000 claims description 25
- 229920002635 polyurethane Polymers 0.000 claims description 25
- 229920006393 polyether sulfone Polymers 0.000 claims description 20
- 239000004952 Polyamide Substances 0.000 claims description 18
- 239000004695 Polyether sulfone Substances 0.000 claims description 18
- 229920002647 polyamide Polymers 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 15
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 210000002919 epithelial cell Anatomy 0.000 claims description 6
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 230000021164 cell adhesion Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 9
- 238000012986 modification Methods 0.000 abstract description 4
- 230000004048 modification Effects 0.000 abstract description 4
- 238000007667 floating Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 74
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 229920000642 polymer Polymers 0.000 description 61
- 239000002609 medium Substances 0.000 description 49
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 238000002474 experimental method Methods 0.000 description 30
- 210000001185 bone marrow Anatomy 0.000 description 28
- 238000009987 spinning Methods 0.000 description 28
- 239000000835 fiber Substances 0.000 description 27
- 230000003698 anagen phase Effects 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 23
- 239000003570 air Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 229920001600 hydrophobic polymer Polymers 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 20
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 108010067306 Fibronectins Proteins 0.000 description 19
- 102000016359 Fibronectins Human genes 0.000 description 19
- 239000012530 fluid Substances 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 229920001477 hydrophilic polymer Polymers 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 10
- 102000004142 Trypsin Human genes 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 229920001519 homopolymer Polymers 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000004382 potting Methods 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000010899 nucleation Methods 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- WPPOGHDFAVQKLN-UHFFFAOYSA-N N-Octyl-2-pyrrolidone Chemical compound CCCCCCCCN1CCCC1=O WPPOGHDFAVQKLN-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- -1 polytetrafluoroethylene Polymers 0.000 description 8
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 229940113088 dimethylacetamide Drugs 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229920002239 polyacrylonitrile Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 102000006354 HLA-DR Antigens Human genes 0.000 description 5
- 108010058597 HLA-DR Antigens Proteins 0.000 description 5
- 102100030856 Myoglobin Human genes 0.000 description 5
- 108010062374 Myoglobin Proteins 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 229920003081 Povidone K 30 Polymers 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920006254 polymer film Polymers 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 229940123973 Oxygen scavenger Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229930188620 butyrolactone Natural products 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920001480 hydrophilic copolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940048895 meronem Drugs 0.000 description 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000011536 re-plating Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012090 tissue culture technique Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004425 Makrolon Substances 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000011016 integrity testing Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- TVPFLPJBESCUKI-UHFFFAOYSA-M potassium;n,n-dimethylcarbamodithioate Chemical compound [K+].CN(C)C([S-])=S TVPFLPJBESCUKI-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0081—After-treatment of organic or inorganic membranes
- B01D67/009—After-treatment of organic or inorganic membranes with wave-energy, particle-radiation or plasma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/022—Filtration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Manufacturing & Machinery (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- External Artificial Organs (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (14)
- 4 내지 100 부피% 농도의 산소의 존재 하에 12.5 kGy 내지 175 kGy의 선량으로 감마선 또는 베타선 또는 전자빔에 의해 조사된, 폴리설폰, 폴리에테르설폰 또는 폴리아릴에테르설폰, 및 폴리비닐피롤리돈을 포함하는 멤브레인.
- 제1항에 있어서, 폴리우레탄을 더 포함하는 멤브레인.
- 제1항 또는 제2항에 있어서, 폴리아미드를 더 포함히는 멤브레인.
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 상기 멤브레인이 중공 섬유 멤브레인(hollow fiber membrane)인 멤브레인.
- 제1항 내지 제3항 중 어느 하나의 항에 있어서, 상기 멤브레인이 평평한 시이트 멤브레인(flat sheet membrnae)인 멤브레인.
- 제1항 내지 제5항 중 어느 하나의 항의 멤브레인을 제조하는 방법으로서, 폴리설폰, 폴리에테르설폰 또는 폴리아릴에테르설폰, 및 폴리비닐피롤리돈을 포함하는 예비 형성된 멤브레인을 4 내지 100 부피% 농도의 산소의 존재 하에 12.5 kGy 내지 175 kGy의 선량으로 감마선 또는 베타선 또는 전자빔으로 조사하는 단계를 포함하는 방법.
- 제1항 내지 제5항 중 어느 하나의 항에 따른 멤브레인 또는 제6항에 따라 제조된 멤브레인을 포함하는 세포 배양 장치.
- 세포, 및 제1항 내지 제5항 중 어느 하나의 항에 따른 멤브레인 또는 제6항에 따라 제조된 멤브레인을 포함하는, 체액을 체외 처리하기 위한 장치.
- 세포를 배양하기 위한, 제1항 내지 제5항 중 어느 하나의 항에 따른 멤브레인 또는 제6항에 따라 제조된 멤브레인의 용도.
- 제9항에 있어서, 상기 세포가 유착 세포인 용도.
- 제10항에 있어서, 상기 세포가 간엽 줄기 세포인 용도.
- 제10항에 있어서, 상기 세포가 간세포인 용도.
- 제10항에 있어서, 상기 세포가 신장 세포인 용도.
- 제10항에 있어서, 상기 세포가 상피 세포인 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08016834A EP2168666A1 (en) | 2008-09-25 | 2008-09-25 | Irradiated membrane for cell expansion |
EP08016834.7 | 2008-09-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110086006A true KR20110086006A (ko) | 2011-07-27 |
KR101590666B1 KR101590666B1 (ko) | 2016-02-01 |
Family
ID=40351648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117009458A KR101590666B1 (ko) | 2008-09-25 | 2009-09-23 | 세포 증식을 위한 조사된 멤브레인 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10974201B2 (ko) |
EP (2) | EP2168666A1 (ko) |
JP (2) | JP5596035B2 (ko) |
KR (1) | KR101590666B1 (ko) |
CN (1) | CN102202771B (ko) |
CA (1) | CA2736533C (ko) |
ES (1) | ES2663430T3 (ko) |
PL (1) | PL2331243T3 (ko) |
WO (1) | WO2010034466A1 (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168668A1 (en) | 2008-09-25 | 2010-03-31 | Gambro Lundia AB | Membrane for cell expansion |
EP2177603A1 (en) | 2008-09-25 | 2010-04-21 | Gambro Lundia AB | Device for renal cell expansion |
EP2314672B1 (en) * | 2008-09-25 | 2015-04-15 | Gambro Lundia AB | Hybrid bioartificial kidney |
EP2168666A1 (en) | 2008-09-25 | 2010-03-31 | Gambro Lundia AB | Irradiated membrane for cell expansion |
EP2488629B1 (en) | 2009-10-12 | 2020-03-11 | Terumo BCT, Inc. | Method of assembling a hollow fiber bioreactor |
EP2412798A1 (en) * | 2010-07-27 | 2012-02-01 | Gambro Lundia AB | Biomimetic membrane for cell expansion |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US9017622B2 (en) * | 2012-04-10 | 2015-04-28 | Lightship Medical Limited | Calibrator for a sensor |
CN102980840A (zh) * | 2012-11-02 | 2013-03-20 | 青岛佳明测控科技股份有限公司 | β射线法颗粒物校准用标准质量膜片的制作方法 |
WO2014123516A1 (en) * | 2013-02-06 | 2014-08-14 | Nc Medical Research Inc | Cell therapy for the treatment of neurodegeneration |
FR3040997B1 (fr) * | 2015-09-15 | 2019-12-27 | Arkema France | Composition de solvant(s) comprenant un melange d'une molecule ayant une fonction sulfoxyde et d'une molecule ayant une fonction amide |
EP3162429A1 (en) * | 2015-10-27 | 2017-05-03 | Basf Se | Process for the preparation of a membrane which comprises a polyethersulfone polymer and a polyamide polymer |
JP6323702B2 (ja) | 2015-12-15 | 2018-05-16 | 東洋紡株式会社 | 細胞培養用中空糸膜および中空糸モジュール |
US20190284525A1 (en) * | 2016-07-25 | 2019-09-19 | Ube Industries, Ltd. | Cell preparation method, cell cultivation device, and kit |
JP6907477B2 (ja) * | 2016-07-25 | 2021-07-21 | 宇部興産株式会社 | 細胞培養方法及び細胞培養装置 |
WO2018021364A1 (ja) * | 2016-07-25 | 2018-02-01 | 宇部興産株式会社 | 多重流路培養法 |
CN109496231A (zh) * | 2016-07-25 | 2019-03-19 | 宇部兴产株式会社 | 细胞培养装置、及使用其的细胞培养方法 |
DE102017201630A1 (de) * | 2017-02-01 | 2018-08-02 | Fresenius Medical Care Deutschland Gmbh | Hohlfasermembran mit verbesserter Biokompatibilität |
EP3691775A1 (en) | 2017-10-05 | 2020-08-12 | Fresenius Medical Care Holdings, Inc. | Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same |
KR20200119238A (ko) * | 2018-01-24 | 2020-10-19 | 우베 고산 가부시키가이샤 | 세포 배양 모듈 |
CN115768499A (zh) * | 2020-01-20 | 2023-03-07 | 阿瑞萨生物科技有限责任公司 | 含有细胞膜的装置及其用途 |
CN113004603B (zh) * | 2021-03-05 | 2023-01-10 | 上海碧云天生物技术有限公司 | 一种多用途防蒸发膜及其制备方法 |
DE102022116515A1 (de) | 2022-07-01 | 2024-01-04 | Leibniz-Institut für Oberflächenmodifizierung e.V. | Verfahren zur Herstellung und Veredelung von Polymer-Filtermaterialien |
CN117861447B (zh) * | 2024-01-16 | 2024-12-10 | 深圳市普朗医疗科技股份有限公司 | 一种去红细胞用滤膜及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0550798A1 (de) * | 1991-10-04 | 1993-07-14 | Kawasumi Laboratories, Inc. | Hohlfasermembran auf Basis von Polysulfon |
US5369012A (en) * | 1992-03-26 | 1994-11-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals |
JP2003245526A (ja) * | 2001-12-19 | 2003-09-02 | Toray Ind Inc | 中空糸膜およびその製造方法、中空糸膜モジュールおよびその製造方法 |
JP2006198611A (ja) * | 2004-12-24 | 2006-08-03 | Toray Ind Inc | 分離膜の製造方法およびその分離膜を用いた分離膜モジュールの製造方法 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2199014B1 (ko) | 1972-09-12 | 1975-03-14 | Rhone Poulenc Ind | |
US4749619A (en) | 1985-08-21 | 1988-06-07 | Hospal Industrie | Hollow fibre useful in blood treating processes |
JPS63198979A (ja) * | 1987-02-13 | 1988-08-17 | Sumitomo Electric Ind Ltd | 細胞培養用基材 |
SE460521B (sv) | 1987-08-31 | 1989-10-23 | Gambro Dialysatoren | Permselektiv asymmetriskt membran samt foerfarande foer dess framstaellning |
WO1989001967A1 (en) | 1987-09-03 | 1989-03-09 | Brown University Research Foundation | Blood purification with cultured renal cells |
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US4970034A (en) | 1988-09-23 | 1990-11-13 | W. R. Grace & Co.-Conn. | Process for preparing isotropic microporous polysulfone membranes |
GB8907740D0 (en) | 1989-04-06 | 1989-05-17 | Beam Tech Ltd | Porous articles |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
JPH0541984A (ja) * | 1990-09-07 | 1993-02-23 | Dow Chem Co:The | 攪拌容器における中空繊維においての細胞の増殖 |
US5151227A (en) | 1991-03-18 | 1992-09-29 | W. R. Grace & Co.-Conn. | Process for continuous spinning of hollow-fiber membranes using a solvent mixture as a precipitation medium |
US5549674A (en) | 1992-03-02 | 1996-08-27 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
JPH05308953A (ja) * | 1992-05-13 | 1993-11-22 | Asahi Medical Co Ltd | 細胞培養膜 |
US5344701A (en) * | 1992-06-09 | 1994-09-06 | Minnesota Mining And Manufacturing Company | Porous supports having azlactone-functional surfaces |
US5543465A (en) * | 1993-03-19 | 1996-08-06 | Gambro Dialysatoren Gmbh & Co. | Process for the production of hydrophilic membranes |
US5431817A (en) | 1993-09-13 | 1995-07-11 | W. R. Grace & Co.-Conn. | Bleach resistant polysulfone/polyurethane composite membranes |
DE19514540A1 (de) | 1995-04-20 | 1996-10-24 | Gambro Dialysatoren | Mit Hitze sterilisierbare Membran |
DE69634352T2 (de) * | 1995-06-30 | 2006-01-12 | Toray Industries, Inc. | Methode zur Herstellung einer teildurchlässigen Hohlfasermembran aus Polysulfon |
ATE530253T1 (de) * | 1995-12-11 | 2011-11-15 | Dendreon Corp | Zusammensetzung, kit und verfahren zur zelltrennung |
US6150164A (en) | 1996-09-30 | 2000-11-21 | The Regents Of The University Of Michigan | Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo |
US5954966A (en) | 1997-01-31 | 1999-09-21 | University Of Ottawa | Membrane composition and method of preparation |
DE59804998D1 (de) * | 1997-02-04 | 2002-09-05 | Mat Adsorption Technologies Gm | Membranmodul enthaltend mindestens zwei gruppen von hohlfasermembranen und verfahren zu seiner herstellung |
FR2772639B1 (fr) | 1997-12-24 | 2000-02-04 | Hospal Ind | Utilisation d'un polymere neutre ou cationique pour prevenir l'activation de la phase contact du sang ou du plasma en contact avec une membrane semi-permeable |
JP4211168B2 (ja) | 1999-12-21 | 2009-01-21 | 東レ株式会社 | 透析器の製造方法および滅菌法 |
FR2804328B1 (fr) | 2000-01-27 | 2002-03-15 | Hospal Ind | Membrane semi-permeable non thrombogene et procede de fabrication |
FR2804603B1 (fr) | 2000-02-04 | 2004-01-23 | Rhodia Chimie Sa | Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques |
US6485684B1 (en) | 2000-02-07 | 2002-11-26 | Steris Inc. | Fluid connection system for endoscope reprocessing with controlled leakage |
FR2810552B1 (fr) | 2000-06-26 | 2004-11-19 | Univ Paris Curie | Polymere biocompatible a structure tridimensionnelle a cellules communicantes, procede de preparation et application en medecine et en chirurgie |
US6566126B2 (en) | 2001-06-22 | 2003-05-20 | Fibercell Systems, Inc. | Apparatus and method for growing cells |
WO2003031533A1 (fr) | 2001-10-04 | 2003-04-17 | Toray Industries, Inc. | Matiere hydrophile et son procede de production |
DE10211051A1 (de) | 2002-03-13 | 2003-10-02 | Fresenius Medical Care De Gmbh | Kapillarmembran und Vorrichtung zur Herstellung derselben |
JP2004041341A (ja) * | 2002-07-10 | 2004-02-12 | Toray Ind Inc | 体外循環用リガンド固定化材料およびそれを用いたカラム |
JP2004189724A (ja) * | 2002-11-29 | 2004-07-08 | Toray Ind Inc | 生理活性物質を含む材料およびその製造方法 |
SE0203857L (sv) | 2002-12-20 | 2004-06-21 | Gambro Lundia Ab | Permselektivt membran och förfarande för tillverkning därav |
SE0203855L (sv) | 2002-12-20 | 2004-06-21 | Gambro Lundia Ab | Permselektivt membran |
JP2004305840A (ja) | 2003-04-03 | 2004-11-04 | Toyobo Co Ltd | 中空糸膜の保存方法 |
JP2004321720A (ja) * | 2003-04-30 | 2004-11-18 | Asahi Medical Co Ltd | 中空糸膜型モジュールの製造方法および中空糸膜型モジュール |
US7914805B2 (en) * | 2003-07-31 | 2011-03-29 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent |
FR2859114B1 (fr) | 2003-08-28 | 2005-10-14 | Gambro Lundia Ab | Dispositif de filtration comportant une membrane semi-permeable pour le traitement extracorporel du sang ou du plasma pour prevenir notamment l'activation retardee de la phase contact |
JP3594032B1 (ja) | 2003-08-29 | 2004-11-24 | 東洋紡績株式会社 | 高透水性中空糸膜型血液浄化器 |
JP4738729B2 (ja) * | 2003-09-24 | 2011-08-03 | ニプロ株式会社 | 中空糸型血液処理器の滅菌包装方法 |
JPWO2005063316A1 (ja) * | 2003-12-26 | 2007-12-20 | 公立大学法人大阪府立大学 | 移植可能な生体材料およびその作成方法 |
CN100515548C (zh) * | 2004-08-10 | 2009-07-22 | 尼普洛株式会社 | 聚砜系选择渗透性中空纤维膜组件及其制造方法 |
JP4483651B2 (ja) * | 2005-03-28 | 2010-06-16 | 東洋紡績株式会社 | 血液浄化用モジュールの滅菌方法 |
JP4834812B2 (ja) * | 2005-03-30 | 2011-12-14 | 東レ株式会社 | 体外循環医療カラム用補助用具 |
JP2006304826A (ja) * | 2005-04-26 | 2006-11-09 | Toyobo Co Ltd | 血液浄化器 |
US20060286078A1 (en) | 2005-06-15 | 2006-12-21 | Humes H D | Methods of treating cardiorenal syndrome and hepatorenal syndrome |
US20080214687A1 (en) | 2005-06-20 | 2008-09-04 | Heinz-Joachim Muller | Cross Linking Treatment of Polymer Membranes |
EP1937796A2 (en) | 2005-07-20 | 2008-07-02 | SurModics, Inc. | Polymer coated nanofibrillar structures and methods for cell maintenance and differentiation |
WO2007018242A2 (ja) * | 2005-08-10 | 2007-02-15 | Asahi Kasei Medical Co Ltd | 中空糸膜型血液浄化装置 |
CA2637686A1 (en) | 2006-02-02 | 2007-08-16 | Innovative Bio Therapies | An extracorporeal cell-based therapeutic device and delivery system |
JP2007215569A (ja) * | 2006-02-14 | 2007-08-30 | Asahi Kasei Medical Co Ltd | 血漿成分分離器及び二重濾過血液浄化装置 |
JP4876704B2 (ja) * | 2006-05-09 | 2012-02-15 | 東洋紡績株式会社 | 血液浄化器 |
FR2902670B1 (fr) | 2006-06-22 | 2009-04-24 | Gambro Lundia Ab | Utilisation d'une suspension pour traiter un support a usage medical, support a usage medical, echangeur et dispositif d'adsorption comprenant le support |
JP2009542840A (ja) * | 2006-07-05 | 2009-12-03 | エージェンシー フォー サイエンス, テクノロジー アンド リサーチ | 多孔質ポリマー物品 |
ATE459410T1 (de) * | 2006-07-07 | 2010-03-15 | Gambro Lundia Ab | Membran für die plasmatrennung |
JP5113178B2 (ja) | 2006-10-18 | 2013-01-09 | ガンブロ・ルンディア・エービー | 中空繊維膜および中空繊維膜の製造方法 |
PL2113298T3 (pl) | 2008-04-30 | 2013-11-29 | Gambro Lundia Ab | Membrana kapilarna do hemodializy o poprawionej przepuszczalności i selektywności |
DE102008002315A1 (de) | 2008-06-09 | 2009-12-10 | Voith Patent Gmbh | Verfahren zur Optimierung der Betriebsweise einer Vorrichtung zum Aufwickeln einer Materialbahn in einer Rollenschneidmaschine und Rollenschneidmaschine |
EP2168668A1 (en) | 2008-09-25 | 2010-03-31 | Gambro Lundia AB | Membrane for cell expansion |
EP2177603A1 (en) | 2008-09-25 | 2010-04-21 | Gambro Lundia AB | Device for renal cell expansion |
EP2168666A1 (en) | 2008-09-25 | 2010-03-31 | Gambro Lundia AB | Irradiated membrane for cell expansion |
EP2314672B1 (en) | 2008-09-25 | 2015-04-15 | Gambro Lundia AB | Hybrid bioartificial kidney |
-
2008
- 2008-09-25 EP EP08016834A patent/EP2168666A1/en not_active Withdrawn
-
2009
- 2009-09-23 CA CA2736533A patent/CA2736533C/en active Active
- 2009-09-23 JP JP2011528235A patent/JP5596035B2/ja active Active
- 2009-09-23 PL PL09815648T patent/PL2331243T3/pl unknown
- 2009-09-23 CN CN200980137689.XA patent/CN102202771B/zh active Active
- 2009-09-23 WO PCT/EP2009/006847 patent/WO2010034466A1/en active Application Filing
- 2009-09-23 EP EP09815648.2A patent/EP2331243B1/en active Active
- 2009-09-23 US US13/120,375 patent/US10974201B2/en active Active
- 2009-09-23 ES ES09815648.2T patent/ES2663430T3/es active Active
- 2009-09-23 KR KR1020117009458A patent/KR101590666B1/ko active IP Right Grant
-
2013
- 2013-11-07 JP JP2013231617A patent/JP5792262B2/ja active Active
-
2021
- 2021-03-02 US US17/189,515 patent/US11596902B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0550798A1 (de) * | 1991-10-04 | 1993-07-14 | Kawasumi Laboratories, Inc. | Hohlfasermembran auf Basis von Polysulfon |
US5369012A (en) * | 1992-03-26 | 1994-11-29 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals |
JP2003245526A (ja) * | 2001-12-19 | 2003-09-02 | Toray Ind Inc | 中空糸膜およびその製造方法、中空糸膜モジュールおよびその製造方法 |
JP2006198611A (ja) * | 2004-12-24 | 2006-08-03 | Toray Ind Inc | 分離膜の製造方法およびその分離膜を用いた分離膜モジュールの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US11596902B2 (en) | 2023-03-07 |
CN102202771B (zh) | 2014-12-10 |
PL2331243T3 (pl) | 2018-07-31 |
KR101590666B1 (ko) | 2016-02-01 |
JP5596035B2 (ja) | 2014-09-24 |
US20210178333A1 (en) | 2021-06-17 |
CN102202771A (zh) | 2011-09-28 |
CA2736533C (en) | 2021-09-21 |
JP2014087344A (ja) | 2014-05-15 |
CA2736533A1 (en) | 2010-04-01 |
US10974201B2 (en) | 2021-04-13 |
WO2010034466A1 (en) | 2010-04-01 |
ES2663430T3 (es) | 2018-04-12 |
JP2012503688A (ja) | 2012-02-09 |
US20110263022A1 (en) | 2011-10-27 |
EP2331243B1 (en) | 2018-02-28 |
EP2168666A1 (en) | 2010-03-31 |
JP5792262B2 (ja) | 2015-10-07 |
EP2331243A1 (en) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11596902B2 (en) | Irradiated membrane for cell expansion | |
EP2340106B1 (en) | Membrane for cell expansion | |
AU2009296331B2 (en) | Hybrid bioartificial kidney | |
US9902939B2 (en) | Device for renal cell expansion | |
US10898863B2 (en) | Hollow-fiber membrane and hollow-fiber module for cell culture | |
WO2017104558A1 (ja) | 細胞培養用の中空糸膜および中空糸モジュール | |
EP2412798A1 (en) | Biomimetic membrane for cell expansion | |
JP2015223111A (ja) | 細胞の長期還流培養のための方法及び装置 | |
WO2018062073A1 (ja) | 培養血小板濃縮モジュールおよびそれを用いた血小板製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20110425 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131108 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20141127 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150624 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20160107 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20160126 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20160126 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20181129 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20191119 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20191119 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20201215 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20211111 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20240117 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20241224 Start annual number: 10 End annual number: 10 |